1. Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries
- Author
-
C. H. Cho, Gonzalo Perez, S. C. Kim, Kyung Hyo Kim, Chi-An Chen, Tang-Yuan Chu, Tak Hong Cheung, Misoo C. Ellison, Liu-ming Huang, S. R. Han, M. Sawata, H. Yoshikawa, Suzanne M. Garland, Y. Takeuchi, Michael Ritter, Alain Luxembourg, Neerja Bhatla, R. Samakoses, B. G. Kim, Hextan Y.S. Ngan, S. Murata, Christine Shields, Yong Sang Song, Anuj Walia, C. Y. Lee, Hee-Sug Ryu, Punnee Pitisuttithum, Nae-Fang Twu, J. H. Kang, Sanjay Lalwani, Yuh Cheng Yang, Young Tae Kim, M. Sakamoto, and Erin Moeller
- Subjects
Adult ,Male ,medicine.medical_specialty ,Asia ,Adolescent ,Drug-Related Side Effects and Adverse Reactions ,cervical cancer ,Human Papilloma Virus Vaccine ,Antibodies, Viral ,law.invention ,Young Adult ,Major Articles and Brief Reports ,03 medical and health sciences ,0302 clinical medicine ,Double-Blind Method ,Randomized controlled trial ,law ,vaccine ,Internal medicine ,Humans ,Immunology and Allergy ,Medicine ,Papillomavirus Vaccines ,030212 general & internal medicine ,Child ,human papillomavirus ,Adverse effect ,Papillomaviridae ,9vHPV ,Cervical cancer ,business.industry ,Immunogenicity ,Papillomavirus Infections ,Genitalia, Female ,medicine.disease ,Vaccination ,Clinical trial ,Treatment Outcome ,Infectious Diseases ,030220 oncology & carcinogenesis ,Viruses ,Female ,business ,Immunogenicity Study - Abstract
The 9vHPV vaccine was efficacious, immunogenic, and well-tolerated in Asian participants from 2 international, randomized clinical trials. Data support 9vHPV vaccination programs in Asia., Background A 9-valent human papillomavirus-6/11/16/18/31/33/45/52/58 (9vHPV) vaccine extends coverage to 5 next most common oncogenic types (31/33/45/52/58) in cervical cancer versus quadrivalent HPV (qHPV) vaccine. We describe efficacy, immunogenicity, and safety in Asian participants (India, Hong Kong, South Korea, Japan, Taiwan, and Thailand) from 2 international studies: a randomized, double-blinded, qHPV vaccine-controlled efficacy study (young women aged 16–26 years; NCT00543543; Study 001); and an immunogenicity study (girls and boys aged 9–15 years; NCT00943722; Study 002). Methods Participants (N = 2519) were vaccinated at day 1 and months 2 and 6. Gynecological samples (Study 001 only) and serum were collected for HPV DNA and antibody assessments, respectively. Injection-site and systemic adverse events (AEs) were monitored. Data were analyzed by country and vaccination group. Results 9vHPV vaccine prevented HPV-31/33/45/52/58–related persistent infection with 90.4%–100% efficacy across included countries. At month 7, ≥97.9% of participants seroconverted for each HPV type. Injection-site AEs occurred in 77.7%–83.1% and 81.9%–87.5% of qHPV and 9vHPV vaccine recipients in Study 001, respectively, and 62.4%–85.7% of girls/boys in Study 002; most were mild to moderate. Conclusions The 9vHPV vaccine is efficacious, immunogenic, and well tolerated in Asian participants. Data support 9vHPV vaccination programs in Asia. Clinical Trials Registration NCT00543543; NCT00943722.
- Published
- 2018
- Full Text
- View/download PDF